(21) compared the efficacy and safety of lenvatinib and PD-1 inhibitors with lenvatinib alone in advanced HCC refractory to HAIC and showed that this combination therapy of PD-1 inhibitors plus lenvatinib has promising survival benefits. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.